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Abstract
The dependence of Plasmodium vivax on invasion mediated by Duffy binding protein (DBP) makes this protein a prime
candidate for development of a vaccine. However, the development of a DBP-based vaccine might be hampered by the
high variability of the protein ligand (DBPII), known to bias the immune response toward a specific DBP variant. Here, the
hypothesis being investigated is that the analysis of the worldwide DBPII sequences will allow us to determine the minimum
number of haplotypes (MNH) to be included in a DBP-based vaccine of broad coverage. For that, all DBPII sequences
available were compiled and MNH was based on the most frequent nonsynonymous single nucleotide polymorphisms, the
majority mapped on B and T cell epitopes. A preliminary analysis of DBPII genetic diversity from eight malaria-endemic
countries estimated that a number between two to six DBP haplotypes (17 in total) would target at least 50% of parasite
population circulating in each endemic region. Aiming to avoid region-specific haplotypes, we next analyzed the MNH that
broadly cover worldwide parasite population. The results demonstrated that seven haplotypes would be required to cover
around 60% of DBPII sequences available. Trying to validate these selected haplotypes per country, we found that five out of
the eight countries will be covered by the MNH (67% of parasite populations, range 48–84%). In addition, to identify related
subgroups of DBPII sequences we used a Bayesian clustering algorithm. The algorithm grouped all DBPII sequences in six
populations that were independent of geographic origin, with ancestral populations present in different proportions in
each country. In conclusion, in this first attempt to undertake a global analysis about DBPII variability, the results suggest
that the development of DBP-based vaccine should consider multi-haplotype strategies; otherwise a putative P. vivax
vaccine may not target some parasite populations.
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Introduction
After more than a century of development of malaria control
measures, Plasmodium vivax remains more widely distributed than
Plasmodium falciparum and it is a potential cause of morbidity and
mortality. Around 2.85 billion people live at risk of infection by P.
vivax, with the greatest burden occurring in Middle East, Asia, the
Western Pacific, Central and South America [1,2]. Although
neglected, P. vivax causes important socioeconomic loss, with the
overall global cost of vivax infection estimated as being between
US$1.4–4.0 billion per year [3]. The recent emergence of drug-
resistant strains and severe (sometimes fatal) disease challenges the
traditional view of P. vivax malaria as a benign infection [4,5].
Consequently, the malaria eradication research agenda (MalERA)
placed the P. vivax in the top list of priorities [www.ploscollections.
org/malERA2011].
The complex life cycle of the Plasmodium includes an
erythrocytic phase that is responsible for clinical symptoms of
human malaria. While P. falciparum invades mature as well
immature red blood cells (RBC) through multiple invasion
pathways, P. vivax invades preferentially reticulocytes [6] and
requires mainly the interaction of parasite ligand to Duffy antigen/
receptor for chemokines (DARC) on RBC membrane [7]. The P.
vivax ligand is a 140 kDa micronemal type I membrane protein,
called the Duffy binding protein (DBP), and gene-deletion
experiment showed that DBP plays an important role in the
irreversible junction of the merozoite with host erythrocytes, a key
step of human infection [8]. Cysteine-rich region II of the DBP
(DBPII) comprises erythrocyte binding motif known as Duffy-
binding-like domain (DBL) [9], which is also found in other
erythrocyte binding proteins (erythrocyte binding antigen 175 -
EBA-175, EBA-140 and EBA-181) and in cytoadherent proteins
(Plasmodium falciparum erythrocyte membrane protein 1) [10]. The
crystal structure of the orthologous DBP ligand domain of the
simian malaria Plasmodium knowlesi provided insight into the
molecular basis for receptor recognition of the PvDBP. The
proposed DARC-recognition site of DBP lies in a solvent-
accessible groove on a fairly flat surface and exposed site for
DARC recognition in subdomain 2 of DBPII [11]. Recently,
Bolton and Garry (2011) demonstrated an additional region on
subdomain 1 of DBPII that might be also necessary for DARC
binding [12].
DBPII is an important anti-P.vivax vaccine candidate since
antibodies against this molecule: (i) inhibit in vitro their binding to
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22944DARC; (ii) reduce merozoite invasion of human erythrocytes; and
(iii) confer protection against blood-stage infection [13,14,15,16].
The important role of DBP-DARC interaction is reinforced by
previous studies that showed individuals without DARC on their
erythrocytes surface are highly resistant to P. vivax invasion
[17,18]. In addition, studies developed in Brazil and Papua New
Guinea showed reduced susceptibility to P. vivax infection in
heterozygous carriers of one DARC-negative allele compared to
two DARC-positive allele carriers [19,20]. However, the paradigm
of the absolute dependence on the presence of Duffy on the red
cell for P. vivax infection has been recently questioned for some
findings indicating that P. vivax can infect and cause disease in
Duffy-negative people [21,22,23]. Nevertheless, this situation
seems to occur in specific areas and/or a small proportion of the
populations, thus the epidemiological importance of this alterna-
tive pathway seem to be restricted to specific endemic areas, such
as Madagascar [23].
Analysis of genetic variability from field parasites showed that
the DBP binding domain (region II) is highly polymorphic
[24,25,26,27,28,29,30,31], therefore it might hamper the vaccine
development as some variable residues alter immune recognition
of protein [32,33,34]. The excess of non-synonymous substitutions
observed in DBPII is consistent with the hypothesis of positive
selective pressure acting on this protein domain, and suggests
allelic variation as a mechanism of immune evasion [35]. As
antigenic variation presents a major limitation in successful
vaccine design, we analyzed all DBPII sequences recorded in
GenBank in order to identify the main haplotypes shared among
P. vivax isolates from different malaria-endemic areas and
undertake a detailed analysis of the nucleotide diversity of the
dbpII gene. Here we show the need to include a minimum number
of DBPII haplotypes in a DBP-based vaccine; otherwise no broad
coverage against worldwide P. vivax isolates might be reached.
Materials and Methods
P. vivax isolates
The following 511 Duffy binding protein gene sequences of P.
vivax deposited in GenBank (last update on 13th April 2011) were
downloaded for genetic analyses: the sequence from a reference
strain Sal-I (access number: NC_009911); 113 sequences from
Papua New Guinea isolates (PNG) (DQ156519; Wosera area in
East Sepik Province: AF289480–AF289483, AF289635–AF289
653 and AF291096; Madang town and rural villages within
Madang Province: AY970837–AY970925, AF469515–AF469
602); 17 sequences from Colombia isolates (COL) obtained from
the villages of Villavicencio and Tumaco (U50575–U50590,
DQ156513); 15 sequences from South Korea isolates (SK)
(DQ156515, DQ156522–DQ156523, AF215737–AF215738,
AF220657, AF220659–AF220667); 102 sequences from different
parts of India (IND) (FJ491142–FJ491241); 30 sequences from
Thailand (THAI) (EF219451, EF368159–EF368180, EF379127–
EF379132, EF379134); 100 sequences from Sri Lanka (SLK)
(GU143914–GU144013); 123 sequences from different parts of
Brazil (BRA) (DQ156520, EU812839–EU812960) and eleven
sequences from Iran (IRA) (EU860428–EU860438). Only unique
haplotypes for each individual were analyzed.
Data Analysis
Genetic diversity analysis. DBPII sequences were aligned
and compared using the Clustal W multiple alignment algorithm
in BioEdit Sequence Alignment editor [36] to identify the single
nucleotide polymorphisms (SNPs). Gaps were removed from
alignments because indels (insertions/deletions) and repeats evolve
by different mechanisms than SNPs and might result in false
estimates of biologically significant diversity. The number of
segregating sites (S), haplotypes (H), nucleotide diversity (p),
haplotype diversity (Hd), and the corresponding standard
deviations (SD) were estimated using DnaSP 5.10 software [37].
Between-population differentiation using the pairwise fixation
index FST was measured with Arlequin 3.5 software [38]. Haplotype
construction. Haplotypes (combinations of nucleotides with no
particular weight placed upon any position) were constructed by
using DnaSP 5.10. We removed synonymous SNPs to focus the
analysis only on the protein diversity. Cluster (population) analysis.T o
determine whether our sample could be grouped into genetic
clusters and to infer the number of clusters (K) that best fit the data,
we used the Bayesian clustering method implemented in the
Structure 2.3 software [39,40]. Structure was run 10 times for
K=1–10 for 30,000 Monte Carlo Markov Chain (MCMC)
iterations after burn-in period of 10,000 using the admixture
model and correlated allele frequencies. We did not use prior
information about population origin for each individual
(USEPOPINFO=0). The mean log probability of the data (Ln
P[D]) and its standard deviation was plotted to predict the optimal
value for K. Graphs of Structure results were produced by using
the DISTRUCT program [41].
Results
Polymorphism and genetic differentiation
We compiled 511 sequences from GenBank for the gene fragment
encoding Duffy binding protein region II (DBPII). The population
dataset included sequences from the natural parasite populations of
eight countries (Table 1): Brazil [35], Colombia [25], India and Iran
[30], Papua New Guinea [27,42,43], South Korea [28], Sri Lanka
[31] and Thailand [44]. The average of sample was 64 sequences
(ranged from 11 to 123) per country. By analyzing a region of the
DBPII of 676 bp that is available for the overall dataset, 127
polymorphic sites were identified (ranged from 16 to 73 per country)
with a nucleotide diversity (p) varying between 0.006 and 0.0109
(South Korea and Thailand, respectively). Most of these SNPs (55%)
are singletons, i.e. observed only in one sequence. Despite the wide
range of number of haplotypes per country (ranged from 9 to 73,
mean of 24), the levels of haplotype diversity (Hd) among them were
equally high and quite similar (ranged from 0.922 to 0.993 in Sri
Lanka and Colombia, respectively). In order to remove most potential
sequencing errors that could interfere with the analysis and inter-
pretation of the results, additional analyses were performed excluding
singleton polymorphisms (Table S1). By comparing both analyses a
significant bias could be detected in the number of segregating sites
and haplotypes in South Korea and PNG samples. However,
nucleotide (p) and haplotype diversity (Hd) were not significantly
affected by this further analysis because these diversity parameters
exclude polymorphisms that are present at low frequencies.
To determine how the observed diversity was distributed among
geographic regions, population structure was inferred by measur-
ing genetic differentiation among countries (FST). The highest
differentiation was identified between Colombia and South Korea
(FST=0.384) and the lowest differentiation was detected between
Iran and Brazil (FST=20.011) (Table 1). We repeated the
analyses for FST using the dataset in which singletons were
excluded and no significant differences were observed for FST
values among countries (Table S1).
Haplotype diversity
To focus the analysis on the putative antigenic diversity (i.e.
polymorphisms that change protein sequence), the nonsynon-
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derived for DBPII sequences. In total 46 nsSNPs were identified
among all sequences with most of them being rare (19 nsSNPs with
frequency #1% and 17 with frequency between 1–10%). Only 10
nsSNPs showed allele frequency above 10% in the whole world
(R308S, K371E, G384D, E385K, K386N, H390R, N417K,
L424I, W437R, and I503K). All but one nsSNP were found at the
eight countries with DBP genetic diversity data available, except
for the SNP R308S that was absent in Colombia and South Korea
(Table 2). Moreover we investigated if these polymorphisms were
localized in regions previously identified or predicted as T- or B-
cell epitopes. All but one nsSNP (K371E) are in regions predicted
or experimentally identified as epitope in the DBPII (Table 2).
In further analysis, those 10 most frequent polymorphisms were
used to build predominant DBPII haplotypes circulating in
malaria-endemic areas. Seventy-three haplotypes were defined
for the whole dataset, ranging from 7 to 29 haplotypes per country
(Table S2). In order to determine a minimum number of DBPII
haplotypes (MNH) required to be included in anti-P. vivax vaccine,
we next sought to identify the number of haplotypes per country
able to cover at least 50% of local parasite population. In the
whole dataset, 17 out of 73 haplotypes fitted this criterion: two
haplotypes in South Korea and Sri Lanka; three in Papua New
Guinea, Iran and India; four haplotypes in Brazil and Colombia
and six haplotypes in Thailand (Figure 1 and Table S2). Together,
the 17 haplotypes covers about 70% of worldwide parasite
population. Among them, seven were shared between two or more
areas, being one haplotype (Hap 23, colored in red) found in high
frequency in four countries from two different continents (America
and Asia). This result agrees with those from FST analysis, which
estimated low genetic differentiation between DBPII sequences
from Brazil and Iran, India or Sri Lanka (Table 1, Figure 1 and
Table 1. Estimates of diversity and genetic differentiation for PvDBPII encoding gene among P. vivax isolates.
Population (N) S p (SD) H Hd (SD) FST
BRA COL PNG SK THAI IRA SLK
BRA (123) 21 0.0082 (0.0003) 35 0.935 (0.012) -
COL (17) 16 0.0085 (0.0007) 16 0.993 (0.023) 0.163* -
PNG (113) 73 0.0106 (0.0004) 73 0.981 (0.005) 0.117* 0.196* -
SK (15) 18 0.0060 (0.0013) 10 0.924 (0.053) 0.197* 0.384* 0.234* -
THAI (30) 29 0.0109 (0.0005) 24 0.982 (0.014) 0.083* 0.234* 0.127* 0.177* -
IRA (11) 17 0.0094 (0.0016) 9 0.964 (0.051) 20.011 0.136* 0.063* 0.169* 0.040 -
SLK (100) 27 0.0097 (0.0005) 39 0.922 (0.014) 0.029* 0.186* 0.129* 0.200* 0.101* 0.018 -
IND (102) 38 0.0088 (0.0005) 36 0.923 (0.016) 0.011* 0.183* 0.120* 0.200* 0.077* 0.004 0.018*
All (511) 127 0.0101 (0.0002) 193 0.970 (0.004)
N: number of isolates; S: number of segregating sites; p: average number of nucleotide substitutions per 1000 sites between pairs of sequences (standard deviation, SD);
Hd: haplotype diversity (SD); H: number of haplotypes; FST: Fixation index, a measure of genetic differentiation between populations;
*: FST values with P,0.05. BRA – Brazil, COL – Colombia, IRA – Iran, SK – South Korea, SLK – Sri Lanka, THAI – Thailand, IND – India, PNG – Papua new Guinea.
doi:10.1371/journal.pone.0022944.t001
Table 2. Description of the most frequent nonsynonymous (nsSNPs) polymorphisms used to construct DBPII haplotypes, their
frequencies in each geographic population and presence in described epitopes.
nsSNP
a Frequency
BRA COL IRA SK SLK THAI IND PNG World Epitope
b
R308S 0.073 0.000 0.182 0.000 0.130 0.267 0.098 0.690 0.235 H1, 5
K371E 0.260 0.176 0.182 0.467 0.340 0.200 0.324 0.115 0.254 -
G384D 0.187 0.412 0.455 0.467 0.060 0.233 0.137 0.345 0.211 H3, 45
E385K 0.203 0.176 0.182 0.067 0.200 0.467 0.304 0.097 0.209 H3, 45, 48
K386N 0.228 0.176 0.182 0.067 0.200 0.400 0.304 0.097 0.211 H3, 45, 48
H390R 0.504 0.941 0.636 0.533 0.340 0.433 0.353 0.504 0.456 H3, 45, 48
N417K 0.398 0.412 0.364 0.933 0.360 0.400 0.373 0.336 0.387 M2, Ia *
L424I 0.480 0.412 0.545 1.000 0.490 0.867 0.451 0.681 0.558 M2, 66, Ia
W437R 0.488 0.118 0.455 1.000 0.370 0.633 0.373 0.327 0.417 M3 *
I503K 0.431 0.059 0.636 1.000 0.550 0.567 0.569 0.425 0.497 Id, 1638*
a: Amino acid numbers according to SAL-1 sequence [39] with the first letter representing the amino acid present in Sal-1 sequence and the latter representing the
polymorphism;
b: H1, H3, M2 and M3 are B-cell epitopes [51]; 5 – T and B-cell epitope; 45 and 48 are B-cell epitopes; 66 – T-cell epitope [52,53]; Ia and Id – MHC class I in silico predicted
promiscuous epitopes [35]; 1638 – MHC class II universal epitope [54];
*- polymorphisms that alter the antigenic character of DBPII [32].
doi:10.1371/journal.pone.0022944.t002
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used to develop a DBPII–based vaccine, covers only 10% of
worldwide samples (Hap 12, colored in purple in Figure 1). So far,
Sal-1 DBPII was detected only in three endemic areas (Brazil,
India and PNG), being in very low frequency in other countries
(Figure 1 and Table S2).
Concerning a more global approach for DBP-based vaccine, we
further sought to determine the MNH that will be able to cover
the majority (,50%) of worldwide parasite population indepen-
dent of the region of origin. Seven haplotypes fitted this criterion
and were found in 60% of 511 DBPII sequences of P. vivax
deposited in GenBank (Haplotypes 4, 12, 23, 24, 44, 59, 64 of
Table S2). Considering the distribution of these 7 selected
haplotypes by locality, it was possible to categorize those localities
in two groups (Figure 2). The first group includes Sri Lanka, Iran,
Brazil, India and PNG, where around 50% of the parasites
population will be covered by these haplotypes. The second group
includes South Korea, Thailand and Colombia, where about only
24% (range 12–33%) of parasite isolates will be covered by these
seven selected haplotypes.
Clustering
Aiming to identify related subgroups of DBPII sequences among
parasites circulating in the study countries, individual samples
were clustered to population on the basis of their genotypes,
independent of their geographic location. For that, we used the
clustering method that uses departures from Hardy-Weinberg
equilibrium to detect population structure. The algorithm groups
related individuals into a predefined number of clusters (K), herein
K=1–10. A Bayesian approach is taken to infer the K value that
provides the best fit to the data as measured by the log-likelihood
score. Each individual is then assigned a membership coefficient
(Q) to each of the clusters with majority of the haplotypes being
assigned to only one cluster at ‘‘true’’ K. The estimated log
probability of our data [Ln P(D)] plateaued between K=4–6
(Figure 3A). Simulation studies have shown that once the real K
has been reached, Ln P(D) will typically plateau or continue to
increase slightly, indicating that K=6 provides the best fit to our
data. We show clustering results for K values of 2–6, being each
individual represented by a vertical line, and each ancestral
population in a different color (Figure 3B). To determine whether
the above-defined subgroups were geographically restricted we
Figure 1. Frequency by country of the DBPII haplotypes that cover at least fifty percent of local parasite population. Among the 73
haplotypes defined using the 10 most prevalent nonsynonymous single nucleotide polymorphisms (nsSNPs), 17 haplotypes (each haplotype was
represented by a color) were able to cover at least 50% of each country parasite population: 2 in South Korea (Hap 4 – dark blue and Hap 40 - orange)
and in Sri Lanka (Hap 23 - red and Hap 44 – light blue); 3 in Iran (Hap 4, Hap 23 and Hap 59 – dark green), in India (Hap 12 - purple, Hap 23 and Hap 24
- yellow) and in PNG (Hap 12, Hap 55 – pink and Hap 64 – light green); 4 in Colombia (Hap 9 – light yellow, Hap 27 – dark gray, Hap 30 - green and
Hap 37 - brown) and 4 in Brazil (Hap 12, Hap 23, Hap 24 and Hap 44); 6 in Thailand (Hap 8 – dark brown, Hap 15 – light pink, Hap 21 - blue, Hap 24,
Hap 36 – light gray and Hap 59). The haplotype from Sal-1 reference strain was represented by purple (Hap 12), for haplotype sequences please see
Table S2. The number in parentheses indicates the frequency of the selected haplotypes in the respective country (range from 0.52 to 0.63). Some FST
values among countries are showed and represented by dashed lines.
doi:10.1371/journal.pone.0022944.g001
Figure 2. Frequency of the seven nsSNP haplotypes of DBPII
that cover at least fifty percent of DBPII sequences deposited in
GenBank. Coverage of the selected haplotypes in each country:
countries that at least 50% of parasites are covered by the selected
haplotypes are represented by black bars and countries that less than
50% of the parasites are covered by the selected haplotypes are
represented by grey bars. The selected haplotypes were: 4, 12, 23, 24,
44, 59, 64 (for haplotype sequences see Table S2).
doi:10.1371/journal.pone.0022944.g002
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Korea the analysis supported low levels of differentiation among
geographical regions, with three to six ancestral populations
present in each country (Figure 4).
Discussion
The major pathway used by P. vivax to invade human
reticulocytes depends on the interaction of the DBP with its
cognate receptor, which makes DBP a high priority anti-P. vivax
vaccine candidate. A significant challenge for the development of
DBP-based vaccines is its highly polymorphic nature, which can
biases antibodies response toward a specific DBP variant
[32,33,34]. Engineering vaccines that combine all potential
haplotypes that might be circulating in malaria-endemic areas
could circumvent polymorphism’s limitation; however, it is not
feasible for a highly polymorphic antigen like DBP. Therefore, the
purpose of this study was to identify predominant DBPII
haplotypes that could be included in a putative vaccine, with
potential to induce an immune response against P. vivax circulating
around the world.
By comparing the DBPII diversity found in different countries
worldwide, we demonstrated high levels of haplotype diversity
among P. vivax isolates. The profile of DBPII genetic diversity was
not related with the levels of malaria endemicity, since similar
pattern was observed from areas with low and unstable malaria
transmission, such as Brazil, as well as from highly endemic areas
such as Papua New Guinea. These findings suggested that
recombinationplaysanimportantroleindeterminingthehaplotype
structure of DBPII, as we recently demonstrated [35]. Genetic
recombination of parasites takes place in the vector, as part of the
Plasmodium life cycle, and is likely facilitated by multiplicity of
infections, i.e. the simultaneous infection of a host by more than one
parasite variant. For P. falciparum, the levels of multiplicity of
infection are partially correlated with the levels of transmission
intensities [45]. Nevertheless for P. vivax, strikingly high values of
multiplicity of infection are reported even in regions of low
endemicity such as Brazil and Thailand. Thus, the proportion of
multiple-clone P. vivax infections, estimated by using microsatellites
analyses, range from 49–57% in Brazil [46,47], 10–47% in India
[48,49], 9–60%in Sri Lanka [50] and 52–63%in Thailand [48,49].
This difference in pattern of multiplicity of infections between P.
vivax and P. falciparum could be related with specific biological
features of the P. vivax parasite, such as earlier gametocytogenesis
[51] and relapse [52]. Early gametocytogenesis might allow for a
more efficient transmission to the mosquito vector before symptoms
appear and, thus, before drug treatment is initiated, while relapses
would also enhance transmission and increase the probability of
detecting mixed infections as further inoculations occur.
Besides the role of recombination we have recently demon-
strated that natural selection has an important role in the
generation and maintenance of the genetic diversity of DBPII
[35]. The maintenance of this variability by diversifying selection
presumably helps parasite to evade the host immune recognition
and favors a low-medium frequency of distinct haplotypes. As we
can expect due differences in the endemicity spectrum and
immune response profile, both recombination and selection seem
to be acting differentially among distinct geographical areas. If no
recombination is assumed, we would expect that the number of
described polymorphic sites observed would be arranged into a
maximum of n+1 haplotypes. Here, this profile was found in the
majority of studied countries, some of them with the number of
haplotypes lower than the number of segregating sites (South
Korea and Iran). However, it is important to highlight that the
small number of DBPII sequences available for those two countries
Figure 3. Population structure of the gene encoding DBPII
based on Bayesian cluster analysis using Structure 2.3
software. (A) Plot of the log probability of the data [Ln P(D)] and its
standard deviation (vertical bars) given values for K of 1–10. (B)
Population clustering for K=2–6. Each individual is represented by a
thin vertical color. Each color represents an ancestral population (pop),
and the color of individual represents their proportional membership in
the different populations. Ancestral populations: red, pop1; green,
pop2; blue, pop3; yellow, pop4; pink, pop5 and light blue, pop6. The
figure shown for a given K is based on the highest probability run at
that K.
doi:10.1371/journal.pone.0022944.g003
Figure 4. Population structure for P. vivax sequences of DBPII at K=6.Graphic of Structure results were produced by using the DISTRUCT
program. Individual P. vivax isolate are represented by a thin vertical line from each geographic population showed above the graphic and separated
by a thin black line.
doi:10.1371/journal.pone.0022944.g004
Worldwide Genetic Variability of PvDBP
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e22944might biased the number of haplotypes observed for those regions;
specially, because there was a significant correlation between the
number of haplotypes and sample size (Spearman correlation
coefficient: rs=0.6628, P=0.0139). Interestingly, in two countries,
Brazil and Sri Lanka, the number of haplotypes was higher than
the number of segregating sites, suggesting a major role of
recombination in these areas. At this time, it is not possible to
conclude if the differences on haplotype number could be
consequence of different recombination rates or due to the
different levels of selective pressure.
For the purpose of rationalizing vaccine design will be necessary
to define polymorphisms that represent antigenically distinct
haplotypes. Here, we selected the most frequent nonsynonymous
single nucleotide polymorphisms (nsSNPs) to derive DBPII
haplotypes. Nine out of 10 nsSNPs lay in regions of DBPII that
are immunologically relevant, mapping on previously defined T-
and B-cell epitopes [32,35,53,54,55,56]. Based on these nsSNPs,
we identified a number between two and six DBPII haplotypes,
which will be required to cover 50% of parasite population in each
studied country. Unfortunately, most of those haplotypes were
geographically restricted and we could not find a single high-
frequency haplotype covering all endemic areas. Of note, the
DBPII Sal-1 variant that is currently being used to develop a
DBPII–based vaccine was found so far in low frequency (10%) and
it seems to be restricted to specific geographic areas. Aiming to
avoid geographically restrict DBPII haplotypes, in the next analysis
we determined the MNH that covers at least fifty percent of DBPII
sequences available in GenBank independent of the region of
origin. By using this approach, seven frequent haplotypes were
identified, that broadly cover parasite populations from 5 out of 8
endemic-countries, i.e., Sri Lanka, Iran, Brazil, India and PNG.
These same selected haplotypes were not able to cover parasite
populations from South Korea, Colombia and Thailand; however,
the results for South Korea and Colombia must be interpreted
with caution because of the limited number of sequences available.
Together, these results show that the development of DBP-based
vaccine should considered multi-haplotype strategies. Similar
strategy has been proposed to another polymorphic malaria
vaccine candidate, the P. falciparum Apical Membrane Antigen 1
(PfAMA-1) [57]. By using a similar approach to that used here, the
authors demonstrated that a worldwide collection of PfAMA1
haplotypes could be clustered into six populations that were
independent of geographic location. Because continuous culture of
P. falciparum has been successfully automated for over 30 years
[58], the same authors were able to demonstrate that immuniza-
tion with one member of PfAMA-1 elicited antibodies that block in
vitro parasite invasion against the same subgroup [57]. Altogether,
these two studies provide an important proof of concept that
vaccine against malaria polymorphic antigens should consider
multi-haplotype strategies. Now it remains to be determined
whether those DBPII haplotypes described here could elicit
broadly immune response. Although essential, those studies will
be a difficult task due to limitation on P. vivax culture. Recent
progress in short-term culture of P. vivax field isolates [59,60] and
in vitro DBPII-DARC binding assays [15,61] present new
opportunities to improve understanding of the ability of DBPII
haplotypes to elicit cross-reactive responses against those that are
genetically similar. In addition, these assays might help to define
which polymorphisms determine antigenically different DBPII
haplotypes.
An additional consideration in the malaria vaccines design is the
geographic structuring of the parasite populations because
significant variation among regions would suggest a need for
vaccines to be tailored accordingly. Overall, we detected low to
medium differentiation between countries, except to sequences
from Colombia and South Korea, which showed high differen-
tiation compared to the other regions. Remarkably, the four
haplotypes that covers more than half Colombian parasites were
not shared with any other parasite population, even with the
Brazilian, another Latin America parasite population. The
contrast among-region structuring was confirmed by FST analysis
with whole data set and clustering analysis using the STRUC-
TURE software with the ten selected nsSNPs. The Bayesian
clustering tool identified six subgroups of related DBPII sequences
in the worldwide parasite population. Nevertheless, clustering was
not related to the geographical origin of P. vivax isolates and all
subgroups were present in the eight endemic countries studied,
although in different proportions. Moreover, the large majority of
isolates (.75%) was formed predominantly by only one ancestral
population. Similar pattern was described for P. falciparum
merozoite antigens in a meta-population analysis [62]. In that
study, the merozoite antigens generally had lower levels of
differentiation among countries. In addition, cluster analysis
suggested that haplotypes formed subgroups independent of
geographic origin with high levels of diversity within population.
Thus, to improve probability of broad efficacy, vaccines based on
merozoite antigens as DBPII may incorporate predominant
haplotypes from different regions. Further analysis will be required
to define the stability of the haplotypes in a region over time, as
natural fluctuations can result from frequency dependent selection
or new haplotypes can appear as result of recombination. For
DBP, a single study so far has investigated the dynamic of
asymptomatic P. vivax infections in a cohort of PNG children [63].
By following those children over six-month period, it was possible
to demonstrate that the DBPII dominant haplotypes remained
relatively stable throughout the study. However, it is difficult to
determine the period of time necessary to observe such changes.
The present study comprises the first attempt to undertake a
global analysis about DBPII variability and provides new insights
on future design of a broad-spectrum P. vivax vaccine. Overcome
the limitation of DBP diversity may require the inclusion of
representative haplotypes otherwise a large proportion of the P.
vivax population will be not target.
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